Inhibition of the extrinsic or intrinsic coagulation pathway during pneumonia-derived sepsis

被引:17
作者
Stroo, Ingrid [1 ,2 ]
Ding, Chao [1 ,3 ]
Novak, Andreja [1 ]
Yang, Jack [1 ]
Roelofs, Joris J. T. H. [4 ]
Meijers, Joost C. M. [5 ,6 ]
Revenko, Alexey S. [7 ]
van 't Veer, Cornelis [1 ]
Zeerleder, Sacha [2 ,8 ]
Crosby, Jeff R. [7 ]
van der Poll, Tom [1 ,9 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Ctr Expt & Mol Med, Amsterdam, Netherlands
[2] Sanquin Res, Dept Immunopathol, Amsterdam, Netherlands
[3] Nanjing Univ, Sch Med, Jinling Hosp, Dept Gen Surg, Nanjing, Jiangsu, Peoples R China
[4] Univ Amsterdam, Acad Med Ctr, Dept Pathol, Amsterdam, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Dept Expt Vasc Med, Amsterdam, Netherlands
[6] Sanquin Res, Dept Plasma Prot, Amsterdam, Netherlands
[7] Ionis Pharmaceut Inc, Drug Discovery & Corp Dev, Carlsbad, CA USA
[8] Univ Amsterdam, Acad Med Ctr, Dept Hematol, Amsterdam, Netherlands
[9] Univ Amsterdam, Acad Med Ctr, Div Infect Dis, Amsterdam, Netherlands
关键词
coagulation; factor VII; factor XII; pneumonia; sepsis; C-TERMINAL PEPTIDES; TISSUE FACTOR; HOST-DEFENSE; ISCHEMIA/REPERFUSION INJURY; ESCHERICHIA-COLI; FACTOR-VII; FACTOR-XI; ACTIVATION; BLOCKADE; MICE;
D O I
10.1152/ajplung.00014.2018
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Pneumonia is the most frequent cause of sepsis, and Klebsiella pneumoniae is a common pathogen in pneumonia and sepsis. Infection is associated with activation of the coagulation system. Coagulation can be activated by the extrinsic and intrinsic routes, mediated by factor VII (FVII) and factor XII (FXII), respectively. To determine the role of FVII and FXII in the host response during pneumonia-derived sepsis, mice were treated with specific antisense oligonucleotide (ASO) directed at FVII or FXII for 3 wk before infection with K. pneumoniae via the airways. FVII ASO treatment strongly inhibited hepatic FVII mRNA expression, reduced plasma FVII to similar to 25% of control, and selectively prolonged the prothrombin time. FXII ASO treatment strongly suppressed hepatic FXII mRNA expression, reduced plasma FXII to similar to 20% of control, and selectively prolonged the activated partial thromboplastin time. Lungs also expressed FVII mRNA, which was not altered by FVII ASO administration. Very low FXII mRNA levels were detected in lungs, which were not modified by FXII ASO treatment. FVII ASO attenuated systemic activation of coagulation but did not influence fibrin deposition in lung tissue. FVII ASO enhanced bacterial loads in lungs and mitigated sepsis-induced distant organ injury. FXII inhibition did not affect any of the host response parameters measured. These results suggest that partial inhibition of FVII, but not of FXII, modifies the host response to gram-negative pneumonia-derived sepsis.
引用
收藏
页码:L799 / L809
页数:11
相关论文
共 43 条
[1]   Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial [J].
Abraham, E ;
Reinhart, K ;
Opal, S ;
Demeyer, I ;
Doig, C ;
Rodriguez, AL ;
Beale, R ;
Svoboda, P ;
Laterre, PF ;
Simon, S ;
Light, B ;
Spapen, H ;
Stone, J ;
Seibert, A ;
Peckelsen, C ;
De Deyne, C ;
Postier, R ;
Pettilä, V ;
Sprung, CL ;
Artigas, A ;
Percell, SR ;
Shu, V ;
Zwingelstein, C ;
Tobias, J ;
Poole, L ;
Stolzenbach, JC ;
Creasey, AA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :238-247
[2]   Myeloid-Related Protein-14 Contributes to Protective Immunity in Gram-Negative Pneumonia Derived Sepsis [J].
Achouiti, Ahmed ;
Vogl, Thomas ;
Urban, Constantin F. ;
Rohm, Marc ;
Hommes, Tijmen J. ;
van Zoelen, Marieke A. D. ;
Florquin, Sandrine ;
Roth, Johannes ;
van't Veer, Cornelis ;
de Vos, Alex F. ;
van der Poll, Tom .
PLOS PATHOGENS, 2012, 8 (10)
[4]   2'-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells [J].
Baker, BF ;
Lot, SS ;
Condon, TP ;
ChengFlournoy, S ;
Lesnik, EA ;
Sasmor, HM ;
Bennett, CF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (18) :11994-12000
[5]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[6]   Severe Sepsis and Septic Shock REPLY [J].
Angus, Derek C. ;
van der Poll, Tom .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (21) :2063-2063
[7]   Blockade of tissue factor - Treatment for organ injury in established sepsis [J].
Carraway, MS ;
Welty-Wolf, KE ;
Miller, DL ;
Ortel, TL ;
Idell, S ;
Ghio, AJ ;
Petersen, LC ;
Piantadosi, CA .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (09) :1200-1209
[8]   Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats [J].
Choi, Goda ;
Hofstra, Jorrit-Jan H. ;
Roelofs, Joris J. T. H. ;
Rijneveld, Anita W. ;
Bresser, Paul ;
van der Zee, Jaring S. ;
Florquin, Sandrine ;
van der Poll, Tom ;
Levi, Marcel ;
Schultz, Marcus J. .
CRITICAL CARE MEDICINE, 2008, 36 (01) :204-210
[9]   Thrombin contributes to protective immunity in pneumonia-derived sepsis via fibrin polymerization and platelet-neutrophil interactions [J].
Claushuis, T. A. M. ;
de Stoppelaar, S. F. ;
Stroo, I. ;
Roelofs, J. J. T. H. ;
Ottenhoff, R. ;
van der Poll, T. ;
van't Veer, C. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (04) :744-757
[10]   TISSUE FACTOR PATHWAY INHIBITOR REDUCES MORTALITY FROM ESCHERICHIA-COLI SEPTIC SHOCK [J].
CREASEY, AA ;
CHANG, ACK ;
FEIGEN, L ;
WUN, TC ;
TAYLOR, FB ;
HINSHAW, LB .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (06) :2850-2860